Correlation Between Mineralys Therapeutics, and AnaptysBio

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and AnaptysBio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and AnaptysBio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and AnaptysBio, you can compare the effects of market volatilities on Mineralys Therapeutics, and AnaptysBio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of AnaptysBio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and AnaptysBio.

Diversification Opportunities for Mineralys Therapeutics, and AnaptysBio

0.33

Correlation Coefficient

Mineralys Therapeutics,  AnaptysBio

Weak diversification

The 3 months correlation between Mineralys and AnaptysBio is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and AnaptysBio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AnaptysBio and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with AnaptysBio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AnaptysBio has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and AnaptysBio go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and AnaptysBio

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the AnaptysBio. But the stock apears to be less risky and, when comparing its historical volatility, Mineralys Therapeutics, Common is 1.74 times less risky than AnaptysBio. The stock trades about -0.08 of its potential returns per unit of risk. The AnaptysBio is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  2,496  in AnaptysBio on November 29, 2024 and sell it today you would lose (796.00) from holding AnaptysBio or give up 31.89% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  AnaptysBio

Mineralys Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

AnaptysBio

Risk-Adjusted Performance

Very Weak

Over the last 90 days AnaptysBio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Mineralys Therapeutics, and AnaptysBio

The main advantage of trading using opposite Mineralys Therapeutics, and AnaptysBio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, AnaptysBio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AnaptysBio will offset losses from the drop in AnaptysBio's long position.

The idea behind Mineralys Therapeutics, Common and AnaptysBio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.